Clover Health Investments Corp

Health insurance providers reported a strong second quarter, with revenues beating analysts' consensus estimates by 2.8% while next quarter's revenue guidance came in 1.7% below expectations. Clover Health reported revenues of $743.2 million, up 55.6% year on year, exceeding analysts' expectations by 2%, and its stock is up 1.9% since reporting. CVS Health posted revenues of $106.1 billion, up 7.3% year on year, outperforming analysts' expectations by 6.7%, but its stock is down 10.2% since reporting. Progyny delivered the weakest guidance update among its peers, with revenues of $350.5 million, up 5.3% year on year, and its stock is down 15.3% since the results. On average, share prices of the 12 health insurance providers stocks tracked are down 6.2% since the latest earnings results.

Clover Health Investments reported second-quarter 2026 revenue of US$743.17 million, up from US$477.62 million a year earlier, and swung to net income of US$28 million from a net loss of US$10.58 million. The company also raised its full-year 2026 guidance, now projecting total revenues of US$2.92 billion to US$3.00 billion and GAAP net income of US$20 million to US$35 million. Management attributed the improved performance to strong Medicare Advantage membership growth and benefits from its AI-powered Clover Assistant platform. The company's narrative projects US$4.2 billion revenue and US$73.3 million earnings by 2029, implying 18.9% yearly revenue growth.

Clover Health Investments Corp reported second-quarter 2026 revenue and earnings that exceeded expectations, driven by robust Medicare Advantage membership growth and a lower medical cost ratio. The company raised its full-year 2026 guidance, reflecting confidence in sustained profitability, while its Clover Assistant platform gained traction and non-insurance businesses grew rapidly. CEO Andrew Toy and CFO Ryan Schmidt highlighted disciplined cost management, improved underwriting, and a structural shift in the cost base as key drivers of the strong adjusted EBITDA performance. The company received a 3.5-star rating for the 2026 plan year and is investing to reach the 4-star threshold that would unlock bonus payments. Clover Health expects modest near-term membership growth, focusing on profitable expansion and leveraging its technology to manage medical costs, and maintains a strong balance sheet with no debt.

Health insurance provider stocks tracked by this publication posted a strong first quarter, with revenues beating analyst consensus estimates by 1.4% and next-quarter revenue guidance coming in line. As a group, share prices have risen 37.4% on average since the latest earnings results. Cencora reported revenues of $78.36 billion, up 3.8% year on year but falling short of expectations by 3.9%, leaving its stock flat. CVS Health delivered the biggest beat, with revenues of $100.4 billion up 6.2% year on year and exceeding estimates by 6.3%, driving a 29.2% stock gain. Molina Healthcare's revenues of $10.8 billion, down 3.1% year on year, met expectations but its full-year revenue guidance missed significantly, yet the stock surged 52.6%. Humana's revenues of $39.65 billion, up 23.5% year on year, met estimates and its full-year EPS guidance beat, propelling a 70.4% stock increase. Clover Health achieved the fastest revenue growth at 62% year on year to $749.2 million, beating estimates by 4.8%, and its stock jumped 65.9%.

Counterpart Health released a whitepaper showing that use of its Counterpart Assistant AI platform by primary care physicians is associated with better performance on key care transition measures within Clover Health’s Medicare Advantage population. Members attributed to CA-enabled PCPs had a 33% higher rate of receipt of discharge information and an 11% higher rate of medication reconciliation post-discharge. They also performed 9% higher on the HEDIS Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions measure. The analysis is Counterpart’s eighth retrospective study measuring CA’s clinical impact, building on the data foundation that supported Clover’s number-one HEDIS score nationwide for a PPO Medicare Advantage plan for the last two years.

Clover Health Investments CEO Andrew Toy sold 313,476 shares of common stock on July 1, 2026, for approximately $1.67 million. The transaction was a non-discretionary 'sell to cover' event tied to tax withholding obligations from restricted stock unit vesting, not a shift in executive sentiment. Toy's direct holdings declined by 3.16% to 9,609,825 shares, representing a stake valued at about $51.8 million based on the July 1 closing price of $5.39. The sale came shortly after Clover Health shares reached a multi-year high of $5.59 on June 29, and the company recently reported a 51% year-over-year increase in Medicare Advantage memberships in the first quarter of 2026, driving a 62% revenue jump to $749.2 million.

UBS analyst Jonathan Yong nearly doubled the price target on Clover Health Investments to $4.75 from $2.75 while maintaining a Neutral rating, reflecting improving confidence in the company's operating outlook. Earlier, Canaccord raised its target to $4.20 from $3.20 with a Buy rating, citing strong April and May performance and improving managed care conditions. Clover Health, a Medicare Advantage insurer and healthcare technology company, has a projected five-year EPS growth rate of 51.31%.

Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services, alleging the agency unfairly recalculated Medicare Advantage Star Ratings for competitor Clover Health after finalization, costing Elevance an estimated $115 million in quality bonus payments. The suit claims CMS applied a different standard to Clover Health while denying similar relief to other insurers, creating an uneven competitive landscape. Elevance is asking the court to overturn the decision and restore a consistent ratings process for all Medicare Advantage insurers. The outcome could affect bonus payments and competitive positioning across the industry, with federal spending on Medicare Advantage quality bonuses expected to top $13 billion this year.

Health insurance providers reported strong first-quarter results, with revenues beating analyst consensus estimates by 1.4% on average. Clover Health stood out with revenue of $749.2 million, up 62% year over year and exceeding expectations by 4.8%, while also raising full-year EBITDA guidance. CVS Health posted the biggest beat, with revenue of $100.4 billion, up 6.2% and surpassing estimates by 6.3%. Centene reported $49.94 billion in revenue, up 7.1% and beating by 6.2%, though it lost 1.36 million customers. Molina Healthcare's revenue declined 3.1% to $10.8 billion, missing full-year guidance, and Cencora's revenue of $78.36 billion fell short of estimates by 3.9%. Since reporting, Clover Health's stock has surged 101%, while the group's shares are up 41.9% on average.

StockStory identified Clover Health as a Russell 2000 stock to own for decades, citing exceptional 31.2% annual revenue growth over the last two years, rising adjusted operating profits, and positive free cash flow. The firm flagged Rush Street Interactive and Nelnet as risky, pointing to Rush Street's below-peer operating margin of 6.9% and Nelnet's muted 5.5% annual revenue growth and 8.4% return on equity. Clover Health trades at 57.9 times forward earnings, Rush Street at 44.2 times, and Nelnet at 2.8 times forward sales.

Clover Health’s stock has surged 92.7% over the past six months, reaching a new 52-week high of $5.01 per share, partly driven by solid quarterly results. The company grew its sales at a 25.6% compounded annual growth rate over the last five years, outpacing the average healthcare company. Its adjusted operating margin rose by 25.6 percentage points over the same period, though it remains negative at 2.6% for the trailing 12 months. Free cash flow margin expanded by 14 percentage points over five years, reaching 2.5% for the trailing 12 months. The stock currently trades at 55.6 times forward price-to-earnings.

Jim Cramer acknowledged that Clover Health was a good speculative pick after a caller noted the company reported GAAP profitability in Q1 2026 and guided for full-year profitability. Cramer said he was not bullish enough on the stock but remains focused on UnitedHealth and CVS for the long haul. He had previously described Clover Health as a pure speculation after a quarter where revenues were okay but earnings were not there.

The Centers for Medicare and Medicaid Services is recalculating 2026 Medicare Advantage star ratings for insurers after losing a court case over its methodology, but only plans that see their scores increase will have ratings updated and be allowed to resubmit bids. The recalculation stems from a lawsuit by Clover Health, whose largest plan dropped from 4 stars to 3.5 stars, costing the company about $120 million in bonus payments. A Georgia federal judge ordered CMS to recalculate Clover's rating without 20 disputed measures, and the agency has now voluntarily extended the recalculation to other plans, though it is removing only measures the judge ruled CMS lacked authority to collect, along with some additional unchallenged measures. TD Cowen analysts estimate that if the Clover criteria were applied broadly, UnitedHealthcare's average scores would rise from 4.11 to 4.27, a $500 million benefit, and Elevance's would move from 3.9 to 3.92, a $25 million benefit, but the current approach yields little change for most insurers. CMS noted the recalculation does not affect its right to appeal the ruling, and the move could prompt further lawsuits from insurers unhappy with their ratings.